TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on December 31, 2015. The report details a corporate action regarding the company's equity financing capabilities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific capital market metrics disclosed include:
- ATM Capacity Increase: The company amended its At Market Issuance Sales Agreement (ATM) to allow for an aggregate offering price of up to $175.0 million.
- Remaining Capacity: As of December 31, 2015, approximately $7.0 million of capacity remained on the existing ATM prior to the amendment.
- Recent Sales Price: The last utilization of the ATM occurred in August 2015 at a sales price of approximately $18 per share.
Material Changes
The primary material change is the execution of an Amended and Restated At Market Issuance Sales Agreement on December 31, 2015. This amendment significantly increased the company's ability to raise capital through the issuance of common stock compared to the prior agreement.
Outlook and Management Commentary
The filing indicates the company's intent to secure additional funding capacity. There is no specific forward-looking guidance, risk factor update, or discussion of unusual items provided in this specific report beyond the ATM amendment.
Investor Verification Checklist
- Verify the terms of the Amended and Restated At Market Issuance Sales Agreement (Exhibit 99.1).
- Confirm the total number of shares authorized for sale under the new $175.0 million cap.
- Review subsequent filings to determine if and when the company utilizes the new ATM capacity.
- Check the company's most recent 10-K or 10-Q for full financial position details not included in this 8-K.